title: Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas.
abstract: To determine whether half of the approved dose of gadobenate dimeglumine (MultiHance) is as effective as a full dose of gadoterate meglumine (Dotarem) for qualitative and quantitative cerebral blood volume (CBV) perfusion evaluation at 3T in patients with brain gliomas.
  
  
  
  We enrolled 65 adult patients in an interindividual comparative study. Patients were randomized to one of two study arms: 33 patients received 0.1 mmol/kg body weight (bw) of gadoterate, 32 patients received 0.05 mmol/kg bw of gadobenate. The patients underwent identical examinations at 3T. Arterial input function (AIF), tissue function (TF), and the maximum tumor CBV (CBV_T) were obtained from each patient. The quality of the CBV maps were independently reviewed by two neuroradiologists blinded to the administered contrast agent.
  
  
  
  The administration of a half dose of gadobenate led to a roughly 40% reduction in signal drop compared to that achieved with a full dose of gadoterate (P values for AIF and TF maximum and integral were <0.01); quantitative and qualitative assessment of CBV maps revealed no difference between contrast agents (P values for CBV_T of high- and low-grade gliomas, image quality evaluation were 0.87, 0.48, >0.65, respectively) CONCLUSION: The CBV maps obtained with a half dose gadobenate (0.05 mmol/kg bw) are of comparable diagnostic quality as the corresponding images acquired with a full dose of gadoterate (0.1 mmol/kg bw).
  
  
  
  2 J. Magn. Reson. Imaging 2017;45:500-506.
authors.affiliation: Department of Neuroradiology, University Hospital of Parma, Parma, Italy.
authors.forename: Girolamo
authors.initials: G
authors.lastname: Crisi
authors.affiliation: Department of Medical Physics, University Hospital of Parma, Parma, Italy.
authors.forename: Silvano
authors.identifier: 0000-0002-7972-7362
authors.initials: S
authors.lastname: Filice
authors.affiliation: Bracco Group, Medical and Regulatory Affairs, Konstanz, Germany.
authors.forename: Gunter
authors.initials: G
authors.lastname: Erb
authors.affiliation: Department of Neuroradiology, University Hospital of Parma, Parma, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Bozzetti
mesh_terms: D000328:Adult; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D003287:Contrast Media / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005910:Glioma / Q000000981:diagnostic imaging* / Q000473:pathology*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine
keywords: brain tumors; cerebral blood volume; gadolinium-based contrast agent; perfusion magnetic resonance imaging; relaxivity